Monoclonal Antibody ELISA Kit for Type VIII Collagen Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to quantify type VIII collagen in serum samples, particularly in diseases associated with vascular remodeling and angiogenesis such as fibrosis and cancer, where its role in tumor progression and metastasis is significant.
Innovation Solution
Development of a monoclonal antibody and ELISA kit targeting the C-terminal epitope of the α1 chain of collagen Type VIII, specifically binding to the amino acid sequence SFSGYLLYPM-COOH, allowing for the detection and quantitation of this collagen in serum samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunoassay methods are used, then general collagen detection is possible, but specific quantitation of type VIII collagen in serum samples cannot be achieved
Solution Approach 1:
The patent segments the detection process by using a two-antibody sandwich assay where one antibody (capture antibody) is immobilized on the assay plate and another antibody (detection antibody) is used in solution. This segmentation allows specific targeting of type VIII collagen while maintaining a manageable assay format, resolving the contradiction between measurement precision and device complexity.
Solution Approach 2:
The patent employs an enzymatic intermediary (horseradish peroxidase conjugated to the detection antibody) that mediates the detection signal. This intermediary enables specific quantitation of type VIII collagen through a measurable colorimetric response, achieving both measurement precision for type VIII collagen while using conventional assay technology to avoid excessive complexity.
2Reliability
If existing antibodies are used, then general collagen binding is achieved, but detection of C-terminal epitope of type VIII collagen with high specificity is not possible
Solution Approach 1:
The patent applies preliminary action by immunizing animals with a synthetic peptide corresponding to the C-terminal epitope of type VIII collagen before producing the antibodies. This pre-targeted immunization ensures high specificity for the C-terminal epitope while using conventional animal immunization techniques, thus achieving reliable specific binding without excessive manufacturing complexity.
3Loss of information
If type VIII collagen quantitation is not available, then disease monitoring in fibrosis and cancer cannot be performed, but developing new assays increases development time and cost
Solution Approach 1:
The patent creates a universal assay platform using conventional ELISA technology that can be applied to multiple disease contexts (fibrosis, cancer, angiogenesis). By adapting existing immunoassay methods rather than developing entirely new techniques, the assay provides valuable disease progression information while minimizing development time and leveraging established manufacturing and validation protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody and ELISA kit demonstrate elevated levels of C8-C in idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and various types of cancer, providing a biomarker for disease diagnosis and prognosis, with a robust technical validation showing low detection limits and high specificity.
Implementation Method 1
an antibody which binds to an epitope present at the C-terminus of the collagen type VIII α1 chain
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The invention provides an immunological binding partner specifically reactive with a C-terminal epitope of the al chain of collagen Type VIII or with an N-terminal epitope the mature form of the al chain of collagen Type VIII, and method of immunoassay for detecting or quantitating in a sample the C-terminal epitope or the N-terminal epitope of the mature al chain of collagen type VIII.